<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329172</url>
  </required_header>
  <id_info>
    <org_study_id>2008_47/0928</org_study_id>
    <secondary_id>2009-014869-43</secondary_id>
    <nct_id>NCT01329172</nct_id>
  </id_info>
  <brief_title>Nasal Mucin Oral Supplementation Treatment Respiratory Inflammation Using PUFA in Cystic Fibrosis (CF) Patients</brief_title>
  <acronym>NOSTRIL</acronym>
  <official_title>Impact of Polyunsaturated Fatty Acids n-3 on Nasal Mucins Expression in Cystic Fibrosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background :

      Cystic fibrosis (CF) patients are prone to recurrent pulmonary infection have different
      secreted mucin pattern from healthy subjects. Long chain polyunsaturated fatty acids have
      been shown to influence survival and MUC5B expression in mice model of chronic pulmonary
      infection.

      Method :

      To study the impact of LCPUFA n-3 on MUC5B expression (mRNA level by RT-PCR) collected in
      airway epithelial cells obtained by nasal brushing. The secondary aim is to assess : MUC1,
      MUC2, MUC4, MUC5AC, MUC7 expression (mRNA level) in airway epithelial cells obtained by nasal
      brushing; Lund-Kennedy score; TNK-alpha, IL-6, IL-8 in blood plasma. This study is a double
      parallel, controlled double blind, randomized clinical trial : LCPUFA n-3 (1 g/day) vs
      placebo for 6 weeks. 30 subjects will be included in this study. Primary and secondary study
      end point will be assessed two times: before randomization and after 60 days of treatment.

      Statistical analysis :

      Treatment group and placebo will be compared using U-Mann-Whitney, intention to treat and per
      protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Outcome Measure : Mucin MUC5B (mRNA level) in native airway epithelial cells obtained
      by nasal brushing

      Secondary Outcome Measures : Mucin MUC1, MUC2, MUC4, MUC5AC, MUC7 (mRNA level) in native
      airway epithelial cells obtained by nasal brushing.

      Lund-Kennedy score TNF-alpha, IL-6, IL-8 in plasma
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">September 20, 2010</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expression of Mucin &quot;MUC5B&quot; by measurement of messenger Ribo Nucleic Acid (mRNA) level in native airway epithelial cells obtained by nasal brushing</measure>
    <time_frame>baseline and 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mucin MUC1, MUC2, MUC4, MUC5AC, MUC7 (mRNA level) in native airway epithelial cells obtained by nasal brushing. Lund-Kennedy score TNF-alpha, IL-6, IL-8 in plasma</measure>
    <time_frame>baseline and two months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Dietary Modification</condition>
  <arm_group>
    <arm_group_label>polyunsaturated fatty acids n-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>polyunsaturated fatty acids n-3 (PUFA n-3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sun flower oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>polyunsaturated fatty acids n-3</intervention_name>
    <description>polyunsaturated fatty acids n-3 1 gram per day during two months</description>
    <arm_group_label>polyunsaturated fatty acids n-3</arm_group_label>
    <other_name>PUFA n-3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>sun flower oil with Poly Unsaturated Fatty Acid 1g/day</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>PUFA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Cystic fibrosis patient

          -  Aged 18 to 30 year

          -  No modification of long term therapy (Corticoids, antibiotics, pancreatic extract,
             antiacid) before 4 weeks before randomization

        Exclusion Criteria:

          -  Awaiting transplantation

          -  Patients on anticoagulants

          -  Contraindication to supplementation with polyunsaturated fatty acids

          -  Taking antibiotics in progress ( less than 15 days)

          -  Taking anti- inflammatory ongoing (more than one week per month , steroids , or
             nonsteroidal )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric GOTTRAND, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHRU de Lille et Université Lille 2</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dunkerque Hospital</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lens Hospital</name>
      <address>
        <city>Lens</city>
        <zip>62300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation center</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>April 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2011</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PUFA</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Nasal brushing</keyword>
  <keyword>Mucins</keyword>
  <keyword>Mucin production</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

